Clinical Trial Update: Effect of Roflumilast at Acute Exacerbations of Chronic Obstructive Pulmonary Disease [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating roflumilast during acute exacerbations of chronic obstructive pulmonary disease was terminated, with results posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Roflumilast (roflumilast)

Snippet

Sponsor: AstraZeneca | Conditions: Chronic Obstructive Pulmonary Disease With (Acute) Exacerbation | Phase 2 | Status: TERMINATED | Results posted: 2016-10-24